Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Allergan plc

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Allergan Reports Third Quarter 2019 Financial Results
- Q3 2019 GAAP Net Revenues of $4.05 Billion - 
Tickers AGN
From PR Newswire
Forest Resolves Antitrust Class Action Litigation with Direct Purchasers of Namenda
Allergan plc (NYSE: AGN), today announced that its subsidiaries, Forest Laboratories, LLC, Forest Laboratories, Inc. and Forest Laboratories Holdings Ltd. (collectively "Forest") have reached a... 
Tickers AGN
From PR Newswire
Allergan Declares Fourth Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share
- Dividend to be Paid on December 13, 2019 - 
Tickers AGN
From PR Newswire
FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
-- Approval Marks 11th BOTOX® Therapeutic Indication and Comes 30 Years After the First Indications Were Approved -- 
Tickers AGN
From PR Newswire
Allergan Presents Data From Eleven Abstracts At The 2019 American Society for Dermatologic Surgery (ASDS) in Chicago
Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Society for Dermatologic Surgery Annual Meeting in Chicago, IL October 24-27 2019. 
Tickers AGN
From PR Newswire
Allergan to Report Third Quarter 2019 Financial Results
Allergan plc (NYSE: AGN) today announced it will release third quarter 2019 financial results on Tuesday, November 5, 2019, prior to the open of U.S. financial markets. 
Tickers AGN
From PR Newswire
Allergan Shareholders Approve Proposed Acquisition by AbbVie
Tickers AGN
From PR Newswire
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
- Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year - 
Tickers AGN
From PR Newswire
On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living
-- Allergan launches interactive website, MyGlaucoma.com, to shed light on the burden of the disease, provide patient and caregiver perspectives and resources to help - 
Tickers AGN
From PR Newswire
On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living
-- Allergan launches interactive website, MyGlaucoma.com, to shed light on the burden of the disease, provide patient and caregiver perspectives and resources to help -- 
Tickers AGN
From PR Newswire
Allergan Expands REFRESH® Portfolio With New REFRESH® RELIEVA™ Lubricant Eye Drop Product Line
- A Trifecta of Relief Formulated with HydroCell™ Technology Offers New Artificial Tear Options for Patients Suffering from Eye Dryness - 
Tickers AGN
From PR Newswire
Allergan to Showcase Late-Stage Data in Age-Related Macular Degeneration and Glaucoma at American Academy of Ophthalmology Annual Meeting
- Presentations include a late-breaking Abicipar abstract and topline Phase 3 results of Bimatoprost SR - 
Tickers AGN
From PR Newswire
Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH... 
Tickers ABBV AGN
From PR Newswire
Announcement under the Irish Takeover Rules: Relevant Securities in Issue - September 17, 2019
Tickers AGN
From PR Newswire
Allergan Announces Commencement of Mailing of Proxy Statement
Tickers AGN
From PR Newswire
Allergan Shareholder Meetings Scheduled for October 14, 2019
Tickers AGN
From PR Newswire
Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-re
- Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen 
Tickers AGN
From PR Newswire
Allergan Receives FDA Approval of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula
Allergan plc (NYSE: AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA® XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™... 
Tickers AGN
From PR Newswire
Allergan Announces Settlement with Two Ohio Plaintiffs in Federal Opioid Litigation
Allergan plc (NYSE: AGN) today announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid multidistrict... 
Tickers AGN
From PR Newswire
Allergan Reports Second Quarter 2019 Financial Results
- Q2 2019 GAAP Net Revenues of $4.09 Billion - 
Tickers AGN
From PR Newswire
Allergan to Report Second Quarter 2019 Financial Results
Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.S. financial markets. 
Tickers AGN
From PR Newswire
Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign
Actress encourages women to take active roles in their reproductive health, including researching birth control options 
Tickers AGN
From PR Newswire
Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
Allergan plc (NYSE: AGN) today announced a voluntary worldwide recall of BIOCELL® textured breast implants and tissue expanders. Allergan is taking this action as a precaution following notification of... 
Tickers AGN
From PR Newswire
Allergan Declares Third Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share
- Dividend to be Paid on September 13, 2019 - 
Tickers AGN
From PR Newswire
U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension
-- Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained treatment free for at least 1 year following 3 treatments with Bimatoprost... 
Tickers AGN
From PR Newswire
Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting
-- Allergan MIND™, Allergan's migraine franchise, showcases data highlighting BOTOX® (onabotulinumtoxinA) for Chronic Migraine, and two investigational products: ubrogepant and atogepant -- 
Tickers AGN
From PR Newswire
Allergan Receives FDA Clearance For CoolTone™ Device
MAGNETIC MUSCLE STIMULATION TECHNOLOGY TO STRENGTHEN, TONE AND FIRM MUSCLES 
Tickers AGN
From PR Newswire
FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
--BOTOX® is the First Neurotoxin Treatment Approved to Treat Pediatric Patients, 2 to 17 Years of Age, with Upper Limb Spasticity-- 
Tickers AGN
From PR Newswire
Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
- New Indication Makes VRAYLAR First and Only Dopamine and Serotonin Partial Agonist to Treat the Full Spectrum of Bipolar I Symptoms in Manic, Mixed, and Depressive Episodes - 
Tickers AGN
From PR Newswire
Allergan Announces Updated Presentation Time at the Bernstein Strategic Decisions Conference
Allergan plc (NYSE: AGN) today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35th Annual Strategic Decisions Conference in New York, NY. The... 
Tickers AGN
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.